Guggenheim Capital’s Inspire Medical Systems INSP Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
– Sell
-4,665
Closed -$430K – 1695
2025
Q4
$430K Buy
+4,665
New +$446K ﹤0.01% 1353
2025
Q3
– Sell
-2,798
Closed -$363K – 1622
2025
Q2
$363K Sell
2,798
-82
-3% -$11.9K ﹤0.01% 1329
2025
Q1
$459K Sell
2,880
-58
-2% -$10.5K ﹤0.01% 1233
2024
Q4
$545K Buy
2,938
+654
+29% +$127K ﹤0.01% 1230
2024
Q3
$482K Sell
2,284
-4,498
-66% -$781K ﹤0.01% 1420
2024
Q2
$908K Buy
6,782
+397
+6% +$75.1K 0.01% 1175
2024
Q1
$1.37M Buy
6,385
+639
+11% +$125K 0.01% 1049
2023
Q4
$1.17M Buy
5,746
+728
+15% +$118K 0.01% 1076
2023
Q3
$996K Buy
5,018
+7
+0.1% +$1.76K 0.01% 1114
2023
Q2
$1.63M Sell
5,011
-413
-8% -$118K 0.01% 948
2023
Q1
$1.27M Sell
5,424
-541
-9% -$137K 0.01% 1056
2022
Q4
$1.5M Buy
5,965
+479
+9% +$102K 0.01% 966
2022
Q3
$973K Buy
5,486
+3,744
+215% +$752K 0.01% 1159
2022
Q2
$318K Sell
1,742
-13
-0.7% -$2.59K ﹤0.01% 1753
2022
Q1
$451K Sell
1,755
-249
-12% -$56.9K ﹤0.01% 1717
2021
Q4
$461K Buy
+2,004
New +$489K ﹤0.01% 1718

Other funds holding INSP

Guggenheim Capital's INSP Position: Q1 2026 in Review

Guggenheim Capital sold out of Inspire Medical Systems (INSP) in Q1 2026, closing a stake of 4,665 shares — an estimated $430K sold.

Guggenheim Capital first reported a position in INSP in Q4 2021 and held it in 16 quarters. The position peaked at $1.63M in Q2 2023. 301 funds tracked by Wall St. Rank hold INSP as of Q1 2026.

  • Guggenheim Capital reported no remaining Inspire Medical Systems position as of Q1 2026 after selling out during the quarter.
  • Guggenheim Capital sold 4,665 Inspire Medical Systems shares in Q1 2026, an estimated $430K.
  • Guggenheim Capital first reported a position in Inspire Medical Systems in Q4 2021 and held it in 16 quarters.
  • Guggenheim Capital's Inspire Medical Systems position peaked at $1.63M in Q2 2023.
  • 301 funds tracked by Wall St. Rank held Inspire Medical Systems as of Q1 2026.

Based on Guggenheim Capital's 13F filing for Q1 2026, filed 15 May 2026.